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Resistance of Plasmodium falciparum to antimalarial drugs is a
serious impediment to controlling malaria.1 P. falciparum
resistance to chloroquine was first reported in Africa in 1979,2
while clinical evidence of chloroquine resistance emerged in
South Africa during the mid-1980s.3 This prompted a
standardised chloroquine in vivo therapeutic efficacy study in
Mpumalanga, based on the World Health Organization (WHO)
protocol,4 which demonstrated a parasitological failure rate of
48.4% (unpublished Department of Health Report, 1998),
necessitating chloroquine’s replacement with sulfadoxine-
pyrimethamine (SP) as first-line treatment of uncomplicated 
P. falciparum malaria in Mpumalanga in 1997.5 The in vivo SP
cure rate at introduction in Mpumalanga in 1998 was 94.5%,
with a combined RI and RII resistance of only 5.5%.5 A
subsequent study6 conducted 3 years after SP introduction
demonstrated continued efficacy of SP in the province. In other
African settings, SP monotherapy has not remained effective as
first-line treatment of malaria for long before parasitological
resistance has developed.7 Extensive research now supports the
implementation of artemisinin-based combination therapies to
improve cure rates, decrease malaria transmission and delay
resistance.8,9  To determine whether current levels of SP
resistance remain adequate to support its use in combination
with artesunate, we conducted an in vivo SP therapeutic
efficacy study 5 years after implementation in Mpumalanga.
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Objectives. To assess the therapeutic efficacy of sulfadoxine-
pyrimethamine (SP) after 5 years of use as first-line treatment
of uncomplicated Plasmodium falciparum malaria, and thus
guide the selection of artemisinin-based combination therapy
in Mpumalanga, South Africa.
Design. An open-label, in vivo therapeutic efficacy study of
patients with uncomplicated P. falciparum malaria treated with
a single oral dose of SP, with response to treatment monitored
clinically and parasitologically on days 1, 2, 3, 7, 14, 21, 28
and 42.
Setting. Mangweni and Naas public health care clinics, Tonga
district in rural Mpumalanga.
Subjects, outcome measures and results. Of 152 patients recruited
sequentially, 149 (98%) were successfully followed up for 42
days. One hundred and thirty-four patients (90%)
demonstrated adequate clinical and parasitological response.
Of the 15 patients (10%) who failed treatment, 2 (1.3%) had an
early treatment failure, and polymerase chain reaction
confirmed recrudescent infection in all 13 patients (8.7%) who
had late parasitological (N = 11) or clinical (N = 2) failure.
Gametocyte carriage was prevalent following SP treatment
(84/152) and this has increased significantly since
implementation in 1998 (relative risk 2.77 (confidence interval
1.65 - 4.66); p = 0.00004).
Conclusion. Asexual P. falciparum parasites in Mpumalanga
remain sensitive to SP, with no significant difference between
the baseline cure rate (94.5%) at introduction in 1998, and the
present 90% cure rate (p = 0.14). However, since gametocyte
carriage has increased significantly we recommend that SP be
combined with artesunate in Mpumalanga to reduce
gametocyte carriage and thus decrease malaria transmission
and potentially delay antimalarial resistance.
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Method and materials
Patients
The study was conducted in Tonga health district,
Mpumalanga, between January and June 2002. All patients
with clinical features of malaria presenting at the two 24-hour
primary health care clinics in Mangweni and Naas, were
sequentially tested for P. falciparum infection using the rapid P.
falciparum histadine-rich protein antigen diagnostic test (Core
Malaria Pf, Core Diagnostics, Birmingham, UK). P. falciparum-
positive patients were then recruited according to modified
WHO guidelines, with inclusion criteria being age 2 years or
above, symptomatic uncomplicated P. falciparum infection with
an asexual parasite density above 1 000 parasites/µl blood,
proximity of patient’s home for follow-up, informed consent,
and history of fever or axillary temperature above 37.5°C.
Exclusion criteria included severe malaria, intolerance of oral
therapy, and pregnancy. Criteria for withdrawal included
patient’s request and clinical deterioration necessitating
hospital referral. Baseline data including age, gender, weight
and place of residence were obtained from all study subjects by
trained health staff on enrolment at the two study sites.
Treatment
Patients were treated according to the guidelines of the
Mpumulanga Department of Health (internal publication),
with a single oral administration of SP (Fansidar, Roche,
Gauteng, South Africa) at a dose as close as possible (using
whole tablets) to 25 mg/kg of sulfadoxine and 1.25 mg/kg of
pyrimethamine but not exceeding the maximum dose of 1 500
mg sulfadoxine/75 mg pyrimethamine. After drug
administration, patients were observed for 1 hour. If vomiting
occurred within 30 minutes of drug administration, the full
dose was repeated. If vomiting occurred 30 - 60 minutes after
drug administration, an additional half dose was administered.
Patients with clinical or parasitological treatment failure were
referred to hospital for therapy with quinine.
Laboratory assessment and outcome measures
Clinical and parasitological assessments were conducted
routinely on days 1, 2, 3, 7, 14, 21, 28 and 42 post-treatment. At
each follow-up visit a thick blood smear was taken, body
temperature was recorded and an assessment for adverse
events was completed. Fever was defined as an axillary
temperature exceeding 37.5°C. Parasite density was measured
by counting the number of parasites against 300 leukocytes on
a Giemsa-stained, finger-prick thick blood film, assuming a
standard leukocyte count of 7 500/µl blood. Parasite clearance
time was the period from recruitment to the first of two
successive thick smears with no asexual parasites. Fever
duration was the time that elapsed between recruitment and
axillary temperature being recorded below 37.5°C without a
subsequent recorded increase in temperature.
Response to treatment was assessed according to the 2003
WHO classification for low to moderate transmission areas.10
Adequate clinical and parasitological response (ACPR) was
defined as absence of parasitaemia on day 42 irrespective of
axillary temperature without previously meeting any of the
criteria for early treatment failure or late clinical or
parasitological failure. Early treatment failure was defined as
the development of danger signs or severe malaria on day 1, 2
or 3, in the presence of parasitaemia; parasitaemia on day 3
with axillary temperature ≥ 37.5°C; parasitaemia on day 2
higher than day 0 count; or parasitaemia on day 3 ≥ 25% of
count on day 0. Late clinical failure was defined as the
development of danger signs or severe malaria after day 3 in
the presence of parasitaemia or the presence of parasitaemia
and axillary temperature ≥ 37.5°C on any day from day 4 to
day 42, without previously meeting any of the criteria for early
treatment failure. Late parasitological failure refers to the
presence of parasitaemia on any day from day 7 to day 42 and
axillary temperature < 37.5°C, without previously meeting any
of the criteria for early treatment failure or late clinical failure.
Parasitological success was defined as conversion from a
positive smear at recruitment to a negative smear by day 7,
remaining negative until the end of the 42-day follow-up
period. Levels of resistance were defined as follows: (i) RI
resistance (recrudescence) — a negative blood film before day 7
and reappearance of parasites during the remaining follow-up
period; (ii) RII resistance — axillary temperature ≥ 37.5°C on
day 2 and parasitaemia ≥ 25% of day 0, or axillary temperature
≥ 37.5°C on day 3 and any level of parasitaemia; (iii) RIII
resistance — less than 75% reduction in parasite density by 72
hours.9
Polymerase chain reaction (PCR) amplification of the
polymorphic genetic markers MSP1, MSP2 and GLURP1 was
used to differentiate between true recrudescence and new
infections.11
Ethical considerations
Approval for the study protocol was obtained from the
Mpumulanga Department of Health Ethics Committee and the
University of Cape Town Research and Ethics Committee.
Informed consent was obtained before enrolment from each
patient or the guardians of minors. The recruited subjects were
informed that they were free to withdraw their consent at any
time during the study. Treatment was provided free of charge,
as is the norm for public-sector malaria treatment in
Mpumalanga.
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Results
Baseline information
One hundred and fifty-two patients were recruited between
January and June 2002. Three patients (2%) moved from the
study area on day 2 (N = 2) or day 7 (N = 1), and were
therefore unable to complete follow-up. Baseline characteristics
are summarised in Table I. The mean dose of pyrimethamine
administered was 1.59 mg/kg with 32/152 (21%) receiving less
than the recommended 1.25 mg/kg dose of pyrimethamine.
Clinical and parasitological responses
Median fever clearance time was 69 hours and median parasite
clearance time was 72 hours. Of the 149 patients (98%) who
completed follow-up to day 42, 134 (90%) had an adequate
clinical and parasitological response. Fifteen patients (10%)
failed treatment — 2 (1.3%) experienced early treatment failure,
and PCR confirmed recrudescent infection in all 13 patients
(8.7%) who had either late parasitological (N = 11) or late
clinical (N = 2) failure. These recrudescent infections occurred
on day 21 (N = 5), day 28 (N = 3) and day 42 (N = 4).
Gametocyte carriage was prevalent throughout follow-up, and
peaked on day 14 when 67/146 study subjects (45.9%) carried
gametocytes (Fig. 1). Intention-to-treat analysis of the
prevalance of patients carrying gametocytes at any time
following treatment has increased significantly from 40/132
(30.3%) in 1998 to 52/119 (43.7%) in 2000 (odds ratio (OR) 1.79
(1.03 - 3.10), and to 83/152 (54.6%) in 2002 (OR 2.77 (1.65 - 4.66)).
This trend is highly significant (p = 0.00004, chi square test for
trend).
Clinical adverse event monitoring was conducted
throughout the study and no adverse events were observed.
Discussion
P. falciparum asexual parasites remain sensitive to SP in
Mpumalanga, with a 90% cure rate at 42 days, and only 2
(1.3%) early treatment failures after 5 years of programme use
as first-line treatment for uncomplicated malaria. There was no
statistically significant difference in SP cure rates between
introduction and 3 and 5 years later (chi-square for trend p =
0.14). The baseline data at SP introduction in 1998 demon-
strated the sensitivity of P. falciparum to SP, with a cure rate of
94.7% (125/132) and a combined RI and RII resistance of 5.5%.5
This efficacy was maintained in 2000 when the ACPR rate was
93.3% (111/119).6 No RIII failures were detected in either of
these studies. The sustained clinical and parasitological efficacy
of SP for 5 years in Mpumalanga is in marked contrast to
findings in Malawi, where the SP parasitological failure rate in
patients followed up for 28 days was 51%, 5 years after
implementation of SP as first-line malaria treatment.7
Despite sustained SP efficacy, the prevalence of gametocytes
in 2002 remained high throughout the follow-up period, with
55% of patients carrying gametocytes on at least 1 follow-up
visit.  This significant increase in gametocyte carriage since SP
introduction, despite sustained high asexual parasitological
cure rates, is cause for concern. Increasing gametocyte carriage
may represent an early indication of impending SP therapeutic
failure. Gametocytes are responsible for the ongoing trans-
mission of malaria, as they are the stage in the parasite’s
lifecycle responsible for re-infection of Anopheles mosquito
vectors from infected humans. There are convincing indications
that antimalarial resistance is facilitated by the relatively higher
gametocyte carriage rates in resistant compared with sensitive
infections.12 Treatment for malaria should eliminate asexual
parasites and ideally also reduce gametocyte stages. The
combination with an artemisinin derivative offers the
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Fig 1. Increasing gametocyte prevalence following SP treatment in
Mpumalanga in 1998, 2000 and 2002 (p = 0.00004).Table I. Baseline characteristics of enrolled patients
Number of patients 152
Males (N (%)) 65 (43%)
Females (N (%)) 87 (57%)
Median age (interquartile
range) (yrs) 19 (11.5 - 28)
Mean pyrimethamine dose
(95% CI) (mg/kg) 1.59  (1.51 - 1.65)
Mean haemoglobin
(range) (mg/dl) 12 (6.8 - 17.5)
Mean initial temperature
(95% CI) (°C) 38.1 (37.9 - 38.3)
Geometric mean initial
parasite density
(95% CI) (parasites/µl) 23 087 (18 831 - 28 304)
Patients with mixed
infection (N (%)) 18/152 (11.8%)
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advantage of decreasing gametocyte carriage.13 The recently
published meta-analysis8 of 5 948 individual patients’ data
from 16 randomised trials studying the effect of artesunate
addition to standard treatment of P. falciparum malaria
demonstrated a significant impact of combination therapy
against gametocytaemia, with a summary OR of 0.11 (95%
confidence interval (CI): 0.09 - 0.15) for the presence of
gametocytes at day 7. This meta-analysis demonstrated a mean
decrease in log gametocyte count equivalent to a decrease of
46% (95% CI: 41 - 50%) in the geometric mean gametocyte
count curve.
These findings indicate that combining SP with an
artemisinin-derivative should be highly effective in the
primary treatment of uncomplicated malaria in Mpumalanga.
In areas where SP remains highly effective, this artemisinin-
based combination therapy (ACT) has a number of advantages
over artemether-lumefantrine including greater effectiveness if
patients are only partially adherent (as SP is adminstered as a
single dose); artesunate plus SP, unlike artemether-
lumefantrine (Coartem), is not dependent on fat for absorption;
there are no weight limitations for AS or SP; and drug costs are
currently lower.
Experience from other southern African areas suggests that
ongoing surveillance remains essential. Data from KwaZulu-
Natal14 12 years after introduction of monotherapy with SP
demonstrated an SP parasitological failure rate of 55% on day
14 and 81% at 28 days’ follow-up. Similar findings have
recently been published from Malawi,7 where 10 years after the
implementation of SP the parasitological failure rate was 38%
at day 14 and 73% after 28 days’ follow-up. Although
artemisinin-based combination antimalarial therapy appears to
provide protection against the development of resistance9 and
there are established therapeutic precedents from the treatment
of the other micro-organisms, regular standardised in vivo
evaluations are essential to confirm ongoing efficacy.15
The findings from this study in Mpumalanga support rapid
implementation of the artemisinin-based combination of
artesunate plus SP as first-line treatment of uncomplicated
falciparum malaria in Mpumalanga, coupled with regular
standardised monitoring of treatment efficacy.
This study was nested within the South-east African
Combination Antimalarial Therapy (SEACAT) evaluation which
received core financial support from the United Nations
Development Programme World Bank WHO Special Programmes
in Tropical Diseases Research (WHO TDR).
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